VANCOUVER, BC, Oct. 7, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys\" or the \"Company\" ) announces that it is undertaking a non-brokered private placement financing (the \"Offering\" ) consisting of a minimum of 7,058,824 units of the Company (\"Units\" ) at an issue price of $0.17 per Unit to raise gross proceeds of $1,200,000 and up to a maximum of 9,411,764 Units for gross proceeds of up to $1,600,000. Each Unit will consist of one common share of the Company (each, a \"Share\" ) and one common share purchase warrant (each, a \"Warrant\" ), whereby each Warrant will entitle the holder thereof to acquire one additional Share at an exercise price of $0.40 for a period of 24 months from the date of issuance.
The Offering is expected to close on such date as the Company may determine and, in any event, on or before a date not later than 45 days after the date of this news release, subject to the satisfaction of certain conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including acceptance of the Canadian Securities Exchange. The Company intends to use the proceeds from the Offering to drive more organic pipeline growth by (1) pursuing multiple licensing opportunities and research collaborations with DPX where the Company's platform solutions can address specific needs or gaps, making the Company an attractive 'go-to' partner for targeted immunotherapies; (2) identifying remaining GLP supply or production of (non-GMP) preclinical supply of DPX to be used in conducting research, preclinical supply of DPX+peanut antigen for the peanut allergy vaccine program, and additional proof of concept studies for expanding the DPX formulations in mRNA and neoantigens; (3) initiating DPX food allergy program at McMaster University for conducting a preclinical proof of concept study with a DPX peanut antigen prophylaxis vaccine candidate; (4) filing of new patents and maintaining annuity payments for issued patents; and (5) completing remaining immunological data analysis from MVP-S phase 1 studies to complete data packages and prepare this asset for out-licensing in other tumor types.
The Units will be offered for sale to purchasers pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 Prospectus Exemptions (the \"Listed Issuer Financing Exemption\" or \"LIFE\" ), in each of the Provinces of Canada (except Quebec) and other qualifying jurisdictions. The securities issued and sold pursuant to the Listed Issuer Financing Exemption will not be subject to a 'hold period' pursuant to applicable Canadian securities laws.
In connection with the Offering, the Company may pay finder's fees to eligible finders who introduce subscribers to the Company.
There is an offering document dated October 7, 2025, related to the Offering that can be accessed under the Company's profile on SEDAR+ at www.sedarplus.ca and on the Company's website at https://www.biovaxys.com/. Prospective investors should read this LIFE offering document before making an investment decision.
This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.
The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the \"U.S. Securities Act\" ), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and its HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractory late-stage ovarian cancer.
BioVaxys common shares are listed on the CSE under the stock symbol \"BIOV\" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
Signed "James Passin"
James Passin, Chief Executive Officer
Phone: +1 740 358 0555
This news release includes certain \"forward-looking information\" and \"forward-looking statements\" (collectively \"forward-looking statements\" ) within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as \"expects\", \"anticipates\", \"believes\", \"intends\", \"estimates\", \"potential\", \"possible\", and similar expressions, or statements that events, conditions, or results \"will\", \"may\", \"could\", or \"should\" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the Offering, including the size
Revolutionizing treatment delivery